1. AVXS 101
Recently, AveXis’ gene therapy candidate AVXS-101, the only gene therapy for spinal muscular atrophy currently in human testing, has been granted FDA orphan drug status for treatment of all types of SMA. It was also granted FDA breakthrough therapy designation and fast track designation. Read about it and other SMA therapy developments here.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?